First-in-human phase I “basket” study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors

M Voss (1), B Adamo (2), R Heist (3), L Gandhi (4), C Moulon (5), H Tanaka (5), N Ishii (6), A Vaslin (5), Y Aoki (6), V Nicolas (5), S Brienza (5), C Zanna (5), KT Flaherty (4), J Tabernero (2), J Baselga (1)

Presented at ASCO 2014, Chicago, USA

(1) Memorian Sloan Kettering Cancer Center, New York, USA

(2) Vall d’Hebron University Hospital, Barcelona, Spain

(3) Massachusetts General Hospital Cancer Center, Boston, USA

(4) Dana Faber Cancer Institute, Boston, USA

(5) Debiopharm International SA, Switzerland

(6) Chugai Pharmaceutical Co., Ltd, Tokyo, Japan